These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 9495210

  • 1. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
    Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A.
    Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH, Kelley L, Green D.
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [Abstract] [Full Text] [Related]

  • 3. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J.
    Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
    [Abstract] [Full Text] [Related]

  • 4. The mutation Arg (53)----Trp causes von Willebrand disease Normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor.
    Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler JE.
    Blood; 1992 Feb 01; 79(3):563-7. PubMed ID: 1732004
    [Abstract] [Full Text] [Related]

  • 5. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
    Karlman M, Holmström M, Wiman B.
    Thromb Res; 2011 Jan 01; 127(1):47-50. PubMed ID: 21094987
    [Abstract] [Full Text] [Related]

  • 6. A novel mutation in the D3 domain of von Willebrand factor markedly decreases its ability to bind factor VIII and affects its multimerization.
    Jorieux S, Gaucher C, Goudemand J, Mazurier C.
    Blood; 1998 Dec 15; 92(12):4663-70. PubMed ID: 9845532
    [Abstract] [Full Text] [Related]

  • 7. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D.
    J Thromb Haemost; 2017 Aug 15; 15(8):1607-1619. PubMed ID: 28581694
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.
    Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH, Hemophilia Inhibitor Research Study Investigators.
    J Thromb Haemost; 2015 Jun 15; 13(6):1036-42. PubMed ID: 25780857
    [Abstract] [Full Text] [Related]

  • 9. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
    Favaloro EJ, Mohammed S, Vong R, Pasalic L.
    Methods Mol Biol; 2023 Jun 15; 2663():679-691. PubMed ID: 37204745
    [Abstract] [Full Text] [Related]

  • 10. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
    Mohammed S, Favaloro EJ.
    Methods Mol Biol; 2017 Jun 15; 1646():461-472. PubMed ID: 28804848
    [Abstract] [Full Text] [Related]

  • 11. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
    Nishino M, Nishino S, Sugimoto M, Shibata M, Tsuji S, Yoshioka A.
    Int J Hematol; 1996 Aug 15; 64(2):127-34. PubMed ID: 8854570
    [Abstract] [Full Text] [Related]

  • 12. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
    Zhukov O, Popov J, Ramos R, Vause C, Ruden S, Sferruzza A, Dlott J, Sahud M.
    Haemophilia; 2009 May 15; 15(3):788-96. PubMed ID: 19298374
    [Abstract] [Full Text] [Related]

  • 13. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 May 15; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 14. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF, Blanco-López MJ, Castiñeira MP, Batlle J.
    Am J Hematol; 1992 May 15; 40(1):20-7. PubMed ID: 1566742
    [Abstract] [Full Text] [Related]

  • 15. Von Willebrand disease type 2N: An update.
    Seidizadeh O, Peyvandi F, Mannucci PM.
    J Thromb Haemost; 2021 Apr 15; 19(4):909-916. PubMed ID: 33497541
    [Abstract] [Full Text] [Related]

  • 16. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
    Hilbert L, Nurden P, Caron C, Nurden AT, Goudemand J, Meyer D, Fressinaud E, Mazurier C, INSERM Network on Molecular Abnormalities in von Willebrand Disease.
    Thromb Haemost; 2006 Sep 15; 96(3):290-4. PubMed ID: 16953269
    [Abstract] [Full Text] [Related]

  • 17. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1.
    Schneppenheim R, Budde U, Krey S, Drewke E, Bergmann F, Lechler E, Oldenburg J, Schwaab R.
    Thromb Haemost; 1996 Oct 15; 76(4):598-602. PubMed ID: 8903002
    [Abstract] [Full Text] [Related]

  • 18. New variant of von Willebrand disease with defective binding to factor VIII.
    Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D.
    Blood; 1989 Oct 15; 74(5):1591-9. PubMed ID: 2506947
    [Abstract] [Full Text] [Related]

  • 19. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M, Simoni L, Gringeri A, Mannucci PM.
    Br J Haematol; 1994 Feb 15; 86(2):333-7. PubMed ID: 8199023
    [Abstract] [Full Text] [Related]

  • 20. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization.
    Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oyen F, Schneppenheim S, Schwaab R, Will K, Budde U.
    Thromb Haemost; 2004 Jul 15; 92(1):36-41. PubMed ID: 15213842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.